Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
Sheila M. Hegde, Xiaowen Wang, Ankit Bhatia, Maria Luisa Peña-Peña et autres
BACKGROUND: Aficamten significantly improved both functional capacity and patient-reported health status in patients with symptomatic nonobstructive hypertrophic cardiomyopathy in the phase 3 randomized, placebo-controlled ACACIA-HCM trial (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints in Adults with Non-Obstructive HCM; NCT06081894). Serial echocardiographic …
us, es, br, il, gb, ar, cn, nl, hu, it, dk, de (code pays fourni par la source)
1 citation
Circulation